With the increasing number of individuals with diabetes and obesity, nonalcoholic fatty liver
disease (NAFLD) is becoming increasingly prevalent, affecting one-quarter of adults …

The public health issue of glucolipid metabolic disorders (GLMD) has grown significantly,
posing a grave threat to human wellness. Its prevalence is rising yearly and tends to affect …

Metabolic reprogramming is a hallmark of cancer. However, it is not well known how
metabolism affects cancer progression. We identified that metabolic enzyme acyl-CoA …

Nonalcoholic steatohepatitis (NASH), a common clinical disease, is becoming a leading
cause of hepatocellular carcinoma (HCC). Dual specificity phosphatase 22 (DUSP22, also …

Whether bone marrow modulates systemic metabolism remains unknown. Our recent study
suggested that myeloid-derived growth factor (MYDGF) improves insulin resistance. Here …

Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and this
nomenclature MAFLD was proposed to renovate its former name, non-alcoholic fatty liver …

Nonalcoholic steatohepatitis (NASH) is an unmet clinical challenge due to the rapid
increase in its occurrence but the lack of approved drugs to treat it. Further unraveling of the …

The family of mitogen-activated protein kinases (MAPKs) consists of fourteen members and
has been implicated in regulation of virtually all cellular processes. MAPKs are divided into …

Non-alcoholic fatty liver disease (NAFLD) has become the most epidemic liver disease
worldwide owing to rapid changes in lifestyle over the past few decades. This chronic …

Nonalcoholic fatty liver disease (NAFLD) is an important component of metabolic syndrome
and one the most prevalent liver diseases worldwide. This disorder is closely linked to …